Hypervirulent and Drug-Resistant Klebsiella pneumoniae: Clinical Challenges and Alternative Treatment Strategies Authors: Sulaiman Bani Abdel-Rahman, Hala Altarawneh, Hassan Ahmad Hasan Alfreahat, Khulud A Alhazmi, Ohood S Alharbi, Malaz Gazzaz, Turki M Alharthi, Loui A Ismaeel, Waiel S Halabi, Asim T Sharif, Bayan Redwan, Khalil K Alkuwaity, Wafaa Alhazmi, Bandar Hasan Saleh, Mona A Alqarni, Abdulaziz Alsaedi, Nabeel Hussain Alhussainy, Hatoon A Niyazi, Hanouf A Niyazi, Hind AbdulMajed, Noha A Juma, Karem Ibrahem Published: 2026 ABSTRACT AbstractKlebsiella pneumoniae is a major opportunistic pathogen responsible for a wide range of hospital- and community-acquired infections, including respiratory tract infections, urinary tract infections, meningitis, and liver abscesses. Among its emerging forms, hypervirulent K. pneumoniae (hvKp) has gained global attention due to its heightened virulence and ability to cause severe infections in healthy individuals. hvKp differs from classical K. pneumoniae (cKp) in its clinical presentation, often causing metastatic infections, liver abscesses without biliary disease, and multiple-site involvement. Despite initial antibiotic susceptibility, the recent convergence of hvKp virulence traits with antimicrobial resistance genes—especially those conferring multidrug resistance (MDR) and carbapenem resistance—poses a serious therapeutic challenge. This review highlights the epidemiological and clinical distinctions between hvKp and cKp, emphasizing the limitations of current diagnostic markers like the string test. Furthermore, it explores novel therapeutic strategies beyond conventional antibiotics, focusing on promising alternatives such as bacteriophage therapy and antimicrobial peptides (AMPs). Several phages, including PSKP16, vB_Kpn_F13, and phage cocktails, have demonstrated potent activity against hvKp strains, including biofilm-forming and carbapenem-resistant isolates. Likewise, AMPs such as Osmin, AA139-nanoformulations, and scorpion venom-derived Cm38 show efficacy in preclinical models. These emerging approaches hold potential to combat the rising threat of hvKp, especially strains that are extensively drug-resistant. Continued research and investment are essential to translate these findings into clinical practice and ensure effective management of hypervirulent and resistant K. pneumoniae infections. Introduction The global rise in infections caused by multidrug-resistant (MDR) microorganisms is a growing concern, posing an even greater threat in developing countries. Among these superbugs is Klebsiella pneumoniae, a Gram-negative, rod-shaped bacterium belonging to the order Enterobacterales, known for exhibiting both extensively drug-resistant (XDR) and pan-drug-resistant (PDR) phenotypes.1 Klebsiella pneumoniae is an opportunistic pathogen implicated in nosocomial infections, including respiratory tract infections, meningitis, bloodstream infections, and urinary tract infections.2 Beyond nosocomial infections, K. pneumoniae may also infect healthy individuals in the community, resulting in conditions like liver abscesses, endophthalmitis, and meningitis.3 K. pneumoniae has demonstrated a strong evolutionary capacity through the acquisition of mobile genetic material, giving rise to two major forms— cKp and hypervirulent (hvKp)—each associated with different clinical concerns.4,5 The first documented case of K. pneumoniae leading to a liver abscess accompanied by endophthalmitis occurred in Taiwan in the 1980s, and the strain responsible was subsequently classified as hvKp.6 Although both cKp and hvKp are found worldwide, hvKp infections have markedly increased over the last 30 years, especially in nations within the Asia-Pacific region.7–9 The hvKp has been identified as a separate pathotype, notable for its heightened virulence and its link to severe disease and high mortality rates.10 Most infections caused by hvKp are community-acquired. A distinguishing feature of hvKp is its capacity to cause severe infections in otherwise healthy individuals across all age groups. Infected patients often present with multiple sites of infection or experience metastatic spread—an atypical pattern among other members of the Enterobacteriaceae family. The hallmark clinical manifestation is a liver abscess in the absence of underlying biliary tract disease. Nonetheless, hvKp has the potential to invade nearly all anatomical sites.11 Initially, the hyper-muco-viscous phenotype characterized by a positive string test was considered a distinctive marker for hvKp strains. Subsequent findings, however, have shown that this feature lacks specificity and sensitivity, as it can be present in some cKp strains and absent in certain hvKp strains.12,13 Similarly, chromosomal genes such as those encoding the aerobactin receptor iutA or iroE are found in several cKp strains and cannot be used alone to define an isolate as hypervirulent strains. The same limitation applies to the presence of K1 or K2 capsular types. In contrast, hvKp strains which typically harbour a suite of virulence genes located on large plasmids—such as pK2044 and pLVPK (plasmids encode a suite of genes—especially rmpA, iucA, iroB, and peg-344)—or integrated chromosomal elements (ICEs), which collectively contribute to their hypervirulent phenotype. Among these, specific biomarkers encoded on the virulence plasmids have proven to be the most reliable indicators for distinguishing hvKp from cKp strains.13,14 The convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae has become an emerging global concern, though NDM-producing outbreak cases remain rare. It has been reported that two outbreaks involving hypervirulent and carbapenem-resistant K. pneumoniae (hvCRKP): ST65-KL2 in five transplant patients over three months and ST11-KL64 in ten patients over ten months. Strains K22877 (NDM-5) and K56649 (KPC-2 and NDM-13) showed strong carbapenem resistance and hypervirulence, with K22877 being more virulent. Evolutionary analysis indicated ST65-KL2 arose from hvKp acquiring resistance (CR- hvKp), while ST11-KL64 resulted from CRKP gaining virulence (hv-CRKP). ST65-KL2 developed ciprofloxacin resistance via plasmid acquisition, whereas ST11-KL64 exhibited enhanced virulence and persistence. Genomic comparison showed distinct profiles in resistance and virulence genes.15,16 Moreover, an analysis of 5,036 Chinese genomes (2005–2023) identified 1,538 CR hvKp isolates, mainly carrying blaKPC, blaNDM, or blaOXA-48-like genes. Most strains possessed aerobactin and yersiniabactin virulence genes and belonged to high-risk sequence types (ST11, ST15, ST23). ST11 showed high resistance, while ST23 displayed strong virulence. Core genome analysis revealed extensive clonal spread, especially in eastern China. CR hvKp carried diverse plasmids (IncF, IncH, IncR), including 40 fusion plasmids combining resistance and virulence traits. Chromosomal integration of blaKPC-2 and hv genes, along with class 1 integrons, further enhanced stability and multidrug resistance. These findings underscore the rapid evolution and spread of CR hvKp in China, highlighting the urgent need for genomic monitoring and effective control strategies.17 Additionally, it has been revealed that a 76 MDR K. pneumoniae isolates from a Chinese hospital were analyzed, identifying six MDR-hypervirulent (MDR-hvKp) strains. Genomic and phenotypic analyses revealed multiple plasmids carrying ESBL (blaCTX-M-65, blaSHV-12, blaSHV-158) and carbapenemase (blaKPC-2) genes, along with virulence genes (rmpA, rmpA2, iucABCD, iutA). Notably, a plasmid combining both resistance and virulence genes was detected, indicating plasmid fusion events. These MDR-hvKp strains, particularly ST11, showed high virulence and resistance, posing severe treatment challenges and emphasizing the urgent need for containment and surveillance.18 Notably, in early 2024, the World Health Organization (WHO) reported the worldwide emergence of Klebsiella pneumoniae ST23 strains carrying carbapenemase genes, conferring resistance to last-resort antibiotics. These hypervirulent, drug-resistant strains have been identified in countries across all six WHO regions, including Algeria, Argentina, Australia, Canada, India, Iran, Japan, Oman, the Philippines, Switzerland, Thailand, the UK, and the USA. The coexistence of hypervirulence and antimicrobial resistance presents major challenges for clinical management and infection control. The WHO urges strengthening of laboratory diagnostics, molecular surveillance, and monitoring systems to curb their global spread.19,20 HvKp and cKp differ significantly in their epidemiological and clinical characteristics. HvKp infections typically originate in the community and can affect individuals of all ages, often those who are otherwise healthy. In contrast, cKp infections are more frequently associated with healthcare settings and tend to occur in older individuals with underlying health conditions.14,21–23 Ethnic predisposition has been observed with hvKp, particularly among Asian, Pacific Islander, and Hispanic populations, whereas cKp shows no such ethnic association.23 Hepatic abscesses caused by hvKp commonly arise in the absence of biliary tract disease, unlike those caused by cKp, which are usually linked to biliary pathology. Moreover, hvKp often results in multiple sites infections and has been associated with unusual and severe clinical syndromes such as endophthalmitis, meningitis, brain abscess, necrotizing fasciitis, splenic abscess, and epidural abscess.14 In contrast, cKp infections typically involve a single site and do not usually present with such syndromes. Lastly, hvKp infections are generally monomicrobial with rare involvement of co-pathogens, whereas cKp infections, particularly in abdominal, soft tissue, or catheter-associated cases, often involve multiple pathogens.5,14,23 It has been reported that K. pneumoniae strains associated with liver abscesses in Taiwanese patients were more likely to exhibit a hyper-muco-viscous phenotype compared to non-invasive strains. This phenotype was identified by the formation of viscous strings exceeding 5 mm in length when a bacterial colony was stretched using a loop on an agar plate—an outcome known as a positive string test. A subsequent study reinforced this association, and for some time, strains demonstrating this trait were frequently referred to in the literature as “hypermucoviscous”.11,24 However, the term “hypervirulent K. pneumoniae” (hvKp) eventually gained broader acceptance, reflecting the organism’s enhanced pathogenic potential. In contrast, Pomakova et al later classified strains responsible for most healthcare-associated infections as cKp, thereby delineating the genotypic and phenotypic differences between these two pathotypes. Despite early enthusiasm, the hypermucoviscous phenotype proved to be an unreliable marker for hvKp, as not all hvKp strains exhibit this trait, and some cKp strains can also be hypermucoviscous. The reliance on the positive string test alone to identify hvKp has led to misclassification in several studies, contributing to confusion in the scientific literature.25–27 A study aimed to determine the prevalence of hvKp among healthcare-associated infections (HAIs) in the intensive care units (ICUs) of Tanta University Hospitals and to compare hvKp with classical K. pneumoniae (cKp) regarding antibiotic resistance, virulence potential, and molecular characteristics. A total of 300 ICU patients with HAIs were included. Isolates were identified and subjected to the string test, antibiotic susceptibility testing, biofilm formation assays, and polymerase chain reaction (PCR) analysis for the detection of capsular genes (K1, K2, K57) and virulence genes (rmpA, rmpA2, and iucA). Among 57 K. pneumoniae isolates, 21 (36.8%) were identified as hvKp and 36 (63.2%) as cKp. The cKp group exhibited significantly higher antibiotic resistance compared to hvKp, while biofilm formation was significantly more pronounced in hvKp isolates (p < 0.004). The presence of iucA, rmpA2, and K1 genes was strongly associated with hvKp. Although the string test demonstrated 100% sensitivity and a high negative predictive value for hvKp detection, relying solely on this phenotypic method may be insufficient. Therefore, combining hypermucoviscosity assessment with genetic detection of aerobactin and other virulence determinants is essential for accurate hvKp identification.28 Although early isolates of hvKp were largely susceptible to antibiotics, their management posed considerable challenges. These included the need for prompt initiation of therapy to prevent metastatic spread, timely identification of occult abscesses to ensure effective source control, and the delivery of targeted therapy for specific infection sites, such as the central nervous system, eyes, or prostate. In recent years, a more alarming development has emerged: the convergence of cKp antimicrobial resistance mechanisms with the virulence determinants of hvKp, often located on the same or coexisting plasmids.29,30 This genetic convergence has led to the emergence of MDR and extensively drug-resistant (XDR) hvKp strains. This evolution has occurred through two primary mechanisms: either by hvKp acquiring resistance plasmids or through the insertion of resistance genes directly into its virulence plasmid.31–33 Raising awareness about hvKp and its evolving pathogenic potential is critically important. This report aims to provide a comprehensive overview of our current understanding of this emerging threat, while also highlighting recent advances in therapeutic strategies aimed at managing hvKp infections. Pathogenesis K. pneumoniae can part of the normal microbiota of humans and animals, as well as in various environmental niches.34,35 Acquisition and colonization by K. pneumoniae appear to be necessary prerequisites for infection; however, colonization alone does not invariably result in disease.36–39 Healthy individuals in the community are at risk of developing hvKp infections, whereas such infections are uncommon with cKp strains in this population. While healthy persons may harbor cKp, infection seldom occurs without host compromise. Conversely, colonization by hvKp in healthy individuals is linked to a markedly increased chance of developing an infection. However, the frequency of infection following hvKp colonization and the factors that influence this progression remain poorly understood. Determining the relative contributions of colonization status, bacterial load, host susceptibility, and the virulence level of hvKp strains is a critical area for future research.14 Although the majority of hvKp infections are community-acquired, an increasing number of reports describe hvKp infections emerging within healthcare settings.40,41 This trend is attributed to several factors: increased recognition of antimicrobial-sensitive hvKp strains causing nosocomial infections; the rising prevalence of hvKp strains that have acquired antimicrobial resistance determinants, enhancing their survival and transmission in healthcare settings; and the evolution of XDR cKp strains into hvKp strains through acquisition of the hvKp virulence plasmid.33 Although hvKp infections occur across all ethnic groups, cases reported in Western countries have shown a disproportionate incidence among individuals of Asian descent, which may reflect socioeconomic, environmental, or travel-related factors rather than genetic susceptibility.42 Diabetes has been identified as a significant risk factor for various infections, including those caused by hvKp.43 Males may have a slightly higher susceptibility to hvKp infection compared to females.44 Recurrent episodes of hvKp bacteremia have been associated with reduced levels of IgG2, suggesting a potential link between impaired humoral immunity and susceptibility to hvKp infections.45 For certain hvKp infections, the route of entry is relatively well-defined. Oropharyngeal colonization may lead to pneumonia through microaspiration or macroaspiration of respiratory secretions. Similarly, colonic or perineal colonization may result in urinary tract infections via the ascending pathway, although such occurrences appear to be uncommon in hvKp infections.5 In some patients, cryptogenic liver abscesses caused by K. pneumoniae have been associated with underlying colonic carcinoma.46–48 Although the K. pneumoniae strains were not clearly defined, it is likely that many of them belonged to the hvKp. In healthcare settings, disruptions of mucosal or epithelial barriers—such as those caused by endotracheal tubes, surgical incisions, or catheters—can facilitate bacterial entry and subsequent infection.33 However, in most patients who develop hvKp infections, the initial site of bacterial entry remains unclear. To date, the majority of hvKp infections are community-acquired and tend to occur in otherwise healthy individuals without apparent disruption of mucosal or epithelial barriers. Given that hepatic abscess is the most frequently reported clinical manifestation, it is plausible that hvKp possesses the ability to translocate across the intestinal mucosa and access the liver via portal bacteremia. The presence of a gut-vascular barrier typically serves to prevent indiscriminate translocation of pathogens from the intestinal microbiota into systemic circulation, suggesting that hvKp may have unique mechanisms to bypass or breach this barrier.49 Hypervirulent Klebsiella pneumoniae (hvKp) has emerged as a major global threat, exhibiting greater virulence than classical K. pneumoniae (cKp) and causing severe community-acquired infections, often in healthy individuals. Colonization of the gastrointestinal tract facilitates both community and hospital transmission. Initially identified in Asia as a leading cause of pyogenic liver abscess, hvKp has since spread worldwide, causing diverse infections such as bacteremia, pneumonia, and soft tissue infections, with frequent metastatic spread to the eye, lungs, and central nervous system.50 Clinical and molecular evidence indicates that K. pneumoniae infections often originate from the gastrointestinal tract, although the mechanisms underlying intestinal barrier penetration remain poorly understood. It has been elucidated that both bacteremic and PLA clinical isolates were capable of adhering to and invading intestinal epithelial cells. Confocal microscopy and three-dimensional (3D) imaging confirmed the internalization of K. pneumoniae within three different human colonic cell lines. Using a Transwell system, it demonstrated that these isolates were able to translocate across polarized Caco-2 monolayers without affecting transepithelial electrical resistance or the localization of tight junction proteins ZO-1 and occludin, suggesting a transcellular route of passage. Further mechanistic investigations using specific inhibitors showed that actin and microtubule cytoskeletal components play essential roles in bacterial invasion, as indicated by inhibition with cytochalasin D and nocodazole. Additionally, inhibitors targeting Rho GTPases (ML141), PI3K (LY294002), and Akt1/2 reduced bacterial invasion in a dose-dependent manner, confirming the involvement of Rho family GTPases and the PI3K/Akt signaling pathway. Additionally in a mouse model of gastrointestinal colonization, in vivo invasion of K. pneumoniae into colonic epithelial cells was observed. Collectively, these results provide strong evidence that K. pneumoniae can translocate across the intestinal barrier through active invasion of epithelial cells, utilizing host cytoskeletal and signaling machinery. This mechanism may explain how gut-colonizing K. pneumoniae gains access to extraintestinal sites, leading to systemic infection and disease.51 In humans, colonization with hvKp strains does not consistently lead to infection, indicating that additional factors are necessary for invasive disease to occur. The exact mechanisms by which hvKp crosses mucosal and/or epithelial barriers remain poorly understood.14 One possibility is entry through occult disruptions in the skin, resulting in bacteremia and subsequent dissemination to distant sites—similar to the well-documented mechanism in Staphylococcus aureus infections. Another consideration is that a critical threshold of hvKp colonization in the intestinal tract may be required for translocation and systemic invasion. Supporting this hypothesis, prior exposure to oral antibiotics such as ampicillin or amoxicillin—which lack activity against Klebsiella spp.—has been associated with an increased risk of subsequent hvKp infection, possibly due to suppression of competing microbiota and subsequent overgrowth of hvKp.52 The sensitivity to antimicrobial peptides (Sap) transporter was shown to enhance colonic colonization by the undefined K. pneumoniae strain Ca0437 in a murine intragastric challenge model. Moreover, the Sap transporter has been shown to facilitate the translocation of Ca0437 across intestinal epithelial cell monolayers in vitro and in a murine intragastric challenge model. The sapA gene plays a crucial role in the ability of Klebsiella pneumoniae to adhere to various host epithelial cells, including those of the intestine, lung, urinary bladder, and liver. Deletion of this gene resulted in marked impairment in several key pathogenic processes — notably, reduced translocation across intestinal epithelial monolayers, weakened interactions with macrophages, and diminished induction of proinflammatory cytokines. In a mouse model of gastrointestinal infection, the ΔsapA strain exhibited significantly lower bacterial burdens in the liver, spleen, and intestine, accompanied by a notable reduction in liver abscess formation and overall mortality. These observations highlight the essential contribution of sapA to K. pneumoniae virulence and provide valuable insight into how this pathogen exploits host–pathogen interactions within the gastrointestinal tract to establish systemic infection.53 Virulence-Associated Factors Capsule The association between hypermucoviscosity and hvKp is well-documented, although some exceptions have been reported. One of the primary virulence determinants linked to the viscous phenotype is the polysaccharide capsule that envelops the bacterial surface. Experimental findings using an intranasal infection model demonstrated that mice infected with capsule-deficient (acapsular) strains exhibited significantly prolonged survival and lower bacterial burdens in both the lungs and bloodstream compared to those infected with encapsulated strains. This suggests that the capsule confers protection against host immune responses.54,55 Rather than acting offensively, capsule-mediated resistance appears to function defensively. The capsule enables K. pneumoniae to evade key host immune mechanisms such as phagocytosis, complement activation, antimicrobial peptides, and specific antibody binding, effectively shielding the bacteria and making them more difficult to eliminate.56–59 Notably, hvKp strains typically possess a larger capsule than cKp strains. Isolates from cerebrospinal fluid, in particular, often exhibit a capsule thickness exceeding 2 mm, which is associated with the hyper-muco-viscous phenotype and may enhance bacterial survival.2 However, this prominent capsule also has potential drawbacks. Its considerable thickness may act as a physical barrier that impedes DNA uptake, thereby limiting horizontal gene transfer. This could partly explain why hvKp strains tend to carry fewer antimicrobial resistance genes compared to their classical counterparts.60 The classification of K. pneumoniae into distinct serotypes is largely based on the variability in the polysaccharide composition, structural differences, and antigenic properties of its capsule. To date, at least 79 capsular (K) serotypes have been identified.61 Among these, eight serotypes—namely K1, K2, K5, K16, K20, K54, K57, and KN1—have been particularly associated with hypervirulent K. pneumoniae (hvKp) strains with K1 and K2 being the most frequently reported in clinical isolates.62,63 Genotypic characterization using multilocus sequence typing (MLST) has revealed differences in sequence type (ST) distribution between these serotypes. Specifically, serotype K1 shows a strong association with sequence type ST23, indicating a relatively conserved genetic background. In contrast, serotype K2 exhibits greater sequence-type diversity, being linked to ST25, ST86, ST375, and ST380.63,64 The prevalence of capsular serotypes varies by geographical region. Serotype K1 is predominantly observed in Asian countries, where it is often linked to severe community-acquired infections. On the other hand, K2 serotypes are more frequently detected in isolates from Europe and North America.12,65 In the context of multidrug-resistant hypervirulent K. pneumoniae (MDR-hvKp), capsular type distribution is influenced not only by geographical factors but also by associated sequence types. For instance, serotypes K64 and K47—frequently linked to ST11—are the most common MDR-hvKp strains circulating in China.66 Moreover, in China, 230 K. pneumoniae isolates from bloodstream infections, hospital-acquired pneumonia, and intra-abdominal infections were analyzed for antimicrobial susceptibility, virulence genes, capsular types, and multilocus sequence typing. hvKp, defined by aerobactin presence, accounted for 37.8% of isolates, with prevalence varying geographically (highest in Wuhan, 73.9%; lowest in Zhejiang, 8.3%). Hypermucoviscosity and K1/K2/K20/rmpA genes strongly correlated with hvKp. hvKp caused more liver abscesses, sepsis, and invasive infections. Cancer and diabetes were independent risk factors. Notably, 12.6% of hvKp produced ESBLs, mainly blaCTX-M, with immunocompromised patients on steroids or combination therapy being more affected. The study highlights the high prevalence and geographic variation of hvKp in China and the emerging threat of ESBL-producing hvKp, emphasizing the need for increased clinical awareness.67 Numerous studies have demonstrated that K. pneumoniae strains expressing K1 and K2 capsular serotypes exhibit significantly higher virulence compared to those belonging to other serotypes.68,69 One proposed mechanism underlying this increased virulence involves the absence of certain sugar moieties, such as mannose and rhamnose, in the K1 and K2 capsular polysaccharides. These sugars are typically recognized by mannose-binding lectin receptors on the surface of macrophages, facilitating phagocytic uptake and clearance of the pathogen. The lack of these components in K1 and K2 capsules allows the bacteria to evade recognition by host immune cells, thereby reducing phagocytosis and enhancing their persistence within the host.70,71 Moreover, the presence of sialic acid within the capsular polysaccharide structures of K1 and K2 serotypes further contributes to their enhanced virulence. This component is associated with the hyper-muco-viscous phenotype that characterizes hvKp strains. Sialic acid is believed to play a significant role in promoting resistance to phagocytosis, either through direct inhibition of immune cell recognition or by reinforcing the physical barrier properties of the capsule. Its incorporation into the capsule may help the bacterium mimic host molecules, thereby facilitating immune evasion and enhancing survival in host tissues.72,73 Siderophores Iron is a vital micronutrient required by both hosts and bacteria for various essential metabolic processes. However, its bioavailability in extracellular fluids of the human body is extremely limited due to the poor solubility of ferric iron (Fe3⁺) under physiological conditions. This iron limitation acts as an innate, non-specific defense mechanism against microbial growth. To survive and proliferate in such an iron-restricted environment, pathogenic bacteria have developed specialized strategies to acquire iron efficiently.74,75 Among these strategies, the most widely adopted is the use of siderophore-dependent iron acquisition systems. Siderophores are small, high-affinity iron-chelating molecules that are synthesized intracellularly and secreted into the external environment, where they bind to ferric iron. The resulting iron-siderophore complexes are then recognized by specific outer membrane receptors and transported into the periplasmic space. From there, they are shuttled across the inner membrane via ATP-binding cassette (ABC) transporters. Once inside the cytoplasm, the ferric iron is reduced to the more bioavailable ferrous form (Fe2⁺), enabling its utilization by the bacterial cell.76,77 K. pneumoniae, especially the hvKp strains, siderophore production is markedly elevated—typically 6- to 10-fold higher than in cKp strains.78 HvKp strains produce four main types of siderophores: enterobactin, yersiniabactin, salmochelin, and aerobactin. These siderophores collectively enhance bacterial iron uptake efficiency, support rapid growth, and contribute significantly to the heightened virulence observed in hvKp infections.23 Lipopolysaccharide (LPS) LPS is a critical component of the outer membrane in all gram-negative bacteria, including both cKp and hvKp. Structurally, LPS is composed of three major domains: lipid A, which anchors the molecule to the bacterial membrane and is primarily responsible for its endotoxic activity; an oligosaccharide core; and the O-antigen, a polysaccharide that extends outward from the bacterial surface.23 Among these, the O-antigen plays a significant role in immune evasion by serving as the initial point of contact between the pathogen and the host’s innate immune system. It provides protection against complement-mediated lysis by binding to complement component C3b, thereby interfering with the formation of membrane attack complexes and preventing membrane perforation.79 To date, at least eight O-antigen serotypes have been identified in K. pneumoniae, with O1 being the most prevalent among clinical isolates.80,81 Evidence suggests that the O1 antigen may contribute to bacterial virulence. For instance, the O-antigen in O1:K2 strains has been implicated in subverting macrophage activation and enhancing bacteremia, thereby increasing the lethality of infection.82 It has been reported that a higher prevalence of the O1 serotype in K. pneumoniae liver abscess compared to non-tissue-invasive strains, and demonstrated that mutant strains deficient in O1 antigen exhibited significantly reduced virulence relative to their wild-type counterparts.83 Fimbriae and Adhesive Structures K. pneumoniae expresses various adhesive structures that facilitate colonization and contribute to its pathogenicity. Among these, type 1 and type 3 fimbriae are the most extensively studied and experimentally characterized. Type 3 fimbriae are recognized as classical virulence factors due to their role in promoting biofilm formation on abiotic surfaces. However, their functional role in hvKp remains incompletely understood.84 Genomic analysis of the hvKP reference strain NTUH-K2044 revealed the presence of seven novel fimbrial gene clusters, designated kpa, kpb, kpc, kpd, kpe, kpf, and kfg.85 Notably, kpc fimbriae appear to be highly associated with the K1 capsular serotype, which is often linked to hvKp, suggesting a potential serotype-specific role in virulence. Further insights into the regulation of fimbrial expression were provided by studies using the classical strain K. pneumoniae CG43. It has been demonstrated that type 3 fimbriae expression and associated biofilm formation are influenced by iron availability and are positively regulated by the ferric uptake regulator.86 This finding implies that, in the iron-limited environments typical of in vivo infection, type 3 fimbriae may have a diminished role in hvKp pathogenesis.5 Additionally, despite the presence of fimbrial genes mrkD and fimH, which encode adhesins for type 3 and type 1 fimbriae respectively, hyper-muco-viscous K1 isolates often exhibit low initial adhesion capacity. This is thought to result from the thick hypercapsule characteristic of hvKp, which may mask fimbrial structures and hinder their interaction with host or surface receptors.87 In addition to fimbriae, hvKp strains also commonly harbor a non-fimbrial adhesin known as CF29K. This protein has been implicated in the pathogenesis of K. pneumoniae liver abscess and may be encoded on plasmids carrying other virulence-associated genes, highlighting its potential role as a co-factor in hvKp virulence.88,89 Outer Membrane Proteins (OMPs) OMPs play a crucial role in the virulence of K. pneumoniae, contributing to immune evasion, survival in hostile host environments, and nutrient transport. Among these, OmpA, peptidoglycan-associated lipoprotein (Pal), and murein lipoprotein (LppA) have been particularly implicated in pathogenicity.23,90 In a study using an intraperitoneal infection model, mutants deficient in pal and lppA in the NTUH-K2044 strain exhibited significantly higher LD50 values compared to the wild-type, indicating reduced virulence. The attenuation was likely due to increased susceptibility of these mutants to complement-mediated killing and neutrophil activity91 Interestingly, despite their reduced virulence, the pal and lppA mutants maintained expression of intact K1 and O1 antigens, which elicited robust antibody responses in infected mice. This observation highlights their potential as promising candidates for vaccine development, providing protective antigenicity without the risks associated with virulent strains.23 In addition to these lipoproteins, K. pneumoniae expresses two major porins, OmpK35 and OmpK36, which facilitate passive diffusion of small molecules. Downregulation or loss of these porins is commonly associated with increased antibiotic resistance but comes at the cost of reduced virulence. In a murine peritonitis model, a clinical KLA isolate (NVT2001) deficient in both ompK35 and ompK36 exhibited significantly impaired growth and pathogenicity, facilitating rapid clearance by the host immune system.92 This finding aligns with earlier reports showing that disruption of ompK36 impairs the bacterium’s ability to persist in hepatic tissue due to diminished colonization capacity.93 Furthermore, a novel porin designated KpnO was identified in the NTUH-K2044 strain. Functional deletion of kpnO resulted in reduced capsule production and attenuated virulence, as demonstrated by slower killing of Caenorhabditis elegans compared to wild-type strains.94 Type VI Secretion System (T6SS) A newly identified virulence-associated factor in hvK is the type VI secretion system (T6SS), first recognized through in silico genome analysis. T6SS is a contractile nanomachine structurally analogous to an inverted bacteriophage tail, functioning as a molecular syringe to deliver effector proteins directly into target cells. These effectors can mediate the lysis of eukaryotic cells or confer a competitive advantage by targeting rival prokaryotic cells.95 Although more than 25% of gram-negative bacteria are predicted to encode T6SSs, its functional relevance in hvKp has recently been elucidated. The hvKp reference strain NTUH-K2044 demonstrates a T6SS-dependent competitive advantage, effectively outcompeting Salmonella typhimurium, Escherichia coli, and T6SS-null K. pneumoniae strains in interbacterial competition assays.96,97 Notably, the frequency of T6SS gene clusters is significantly elevated in KLA (Klebsiella liver abscess) strains compared to intestinal-colonizing strains, suggesting that T6SSs enhance hvKp fitness in extraintestinal environments.23 Upon activation, T6SS deploys toxic effectors to kill E. coli strains lacking immunity genes. Similarly, the overexpression of the phospholipase effector Tle1, encoded by a carbapenemase-producing K. pneumoniae strain, significantly inhibited the growth of E. coli, underscoring the system’s antibacterial potency.98 In the hypervirulent strain Kp52.145, the T6SS-associated effector gene pld1, encoding a phospholipase D family protein (PLD1), was identified as a critical virulence determinant. Deletion of pld1 (Δpld1) markedly attenuated virulence in a murine pneumonia model, confirming its functional importance.47 Interestingly, it has been identified that iron acquisition genes located adjacent to the T6SS core component tssD, suggesting a potential role for T6SS in iron uptake—a critical factor for bacterial survival and pathogenicity in iron-limited host environments.46 Clinical Spectrum of hvKp Infections Although hvKp is primarily associated with community-onset infections, hospital-acquired cases have also been reported, including ventilator-associated pneumonia. In addition to classic lobar pneumonia, hvKp is capable of causing a broad range of pulmonary complications such as empyema, lung abscesses, and septic pulmonary emboli. Notably, hvKp has become the leading cause of community-acquired empyema.14,99,100 Abdominal infections, particularly liver abscesses, are hallmark features of hvKp. Pyogenic liver abscess is the most common source in cases of hvKp bacteremia, although other primary sites have been documented.5,14,101 Bacteremia is a frequent and serious complication of hvKp infections, often accompanied by septic thromboembolism that can affect both local regions and distant sites.14,40 Endophthalmitis, a vision-threatening complication, was first linked to hvKp in 1986 and helped distinguish hvKp from cKp. Similarly, hvKp has altered the epidemiology of community-acquired meningitis in Southeast Asia, where it is now a significant pathogen.6,102 hvKp can cause intramuscular abscesses, which may present with or without necrotizing fasciitis. The urinary tract has also been identified as a potential source of hvKp bacteremia.103,104 Infections involving nearly every anatomical site have been reported with hvKp. Less common clinical presentations include orbital cellulitis, epididymitis, and Bartholin’s abscess.105–107 It has been shown that the clinical and microbiological profiles of K. pneumoniae meningitis cases from 2014 to 2020 in a tertiary hospital, focusing on antimicrobial resistance, virulence, and patient outcomes. Among 318 bacterial meningitis cases, 36 (11.3%) were attributed to K. pneumoniae. The most frequent capsular types were K1, K47, and K64 (each 19.4%), while multilocus sequence typing (MLST) identified 14 sequence types, with ST11 being predominant (38.9%). Carbapenem resistance was detected in 44.4% of isolates, and 66.7% were hypervirulent (hvKp), with 36.1% classified as hypervirulent carbapenem-resistant K. pneumoniae (hv-CRKP). Patients infected with hv-CRKP had significantly higher mortality (92.3%) compared to others (56.5%, P < 0.05). The high incidence and fatality of K. pneumoniae meningitis—particularly from hv-CRKP—underscore the urgent need for improved surveillance, early detection, and effective therapeutic strategies to combat these deadly infections.108 It has been reported that an outbreak of ST859-K19 CR- hvKp in a Chinese teaching hospital, a single-locus variant of ST11 not previously described. Eleven nonrepetitive isolates were collected from 11 patients, three of whom died. All isolates were highly resistant to common antibiotics, remaining susceptible only to colistin, tigecycline, and ceftazidime/avibactam. Whole-genome sequencing revealed close clustering, suggesting clonal transmission, and identical resistance (blaKPC-2, blaTEM-1B, blaSHV-187, rmtB, fosA6) and virulence (rmpA, rmpA2, iucABCDiutA) gene profiles. The complete genome of RJ9299 included a 5,445-kb chromosome, a 215-kb virulence plasmid, a 109-kb blaKPC-2 plasmid, and three circular plasmids, with high similarity to known plasmids. Serum resistance and Galleria mellonella assays indicated variable virulence. This first report of ST859 CR- hvKp highlights the need for active surveillance and infection control to prevent clonal spread in healthcare settings.109 Of note, rmpA and rmpA2, these genes regulate the mucoid phenotype by increasing capsule polysaccharide synthesis, producing a hypermucoviscous, anti-phagocytic capsule that shields the bacteria from host immune defenses and promotes survival in the bloodstream.110–113 Also, iutA belongs to the iucABCD-iutA operon, which mediates the synthesis of the aerobactin siderophore, facilitating efficient iron acquisition under iron-restricted conditions within the host—a key determinant of bacterial growth and virulence. Similarly, the iroBCDN operon encodes the salmochelin siderophore, which enables the bacterium to evade host immune proteins such as lipocalin-2, thereby further enhancing its ability to obtain iron and sustain infection.111,113,114 Also, it has been identified a new virulence factor, PEG344, encoded on the hvKp 1 virulence plasmid and widely present among hvKp strains. Functional analysis showed that deletion of peg-344 reduced virulence in mice after pulmonary infection but not after subcutaneous challenge. In silico data indicate that PEG344 acts as an inner membrane transporter, possibly aiding growth in human ascites. These findings enhance understanding of hvKp -specific virulence mechanisms and may support future therapeutic development.113,115 Antimicrobial Resistance Multidrug-resistant hypervirulent Klebsiella pneumoniae (MDR- hvKp) represents a new “superbug,” combining high virulence with strong antibiotic resistance. Emerging cases, especially in China, challenge the belief that hvKp strains are drug-sensitive. MDR- hvKp likely arises from classical K. pneumoniae through gene acquisition.116 Antimicrobial resistance (AMR) in K. pneumoniae, particularly hvKp strains, arises through several distinct and variably occurring mechanisms.117 Antimicrobial resistance in Klebsiella pneumoniae is often driven by the production of extended-spectrum β-lactamases (ESBLs) and carbapenemases. This bacterium may possess clustered regularly interspaced short palindromic repeats (CRISPRs), which act as a defense system against foreign genetic elements like plasmids and bacteriophages. It has been examined the relationship between CRISPR/Cas systems and antibiotic resistance among 100 K. pneumoniae isolates from Iraqi patients. Antimicrobial susceptibility testing and PCR-based detection of CRISPR/Cas systems were conducted. ESBL production was found in 71% of isolates, carbapenem resistance in 15%, while only 14% were fully susceptible. The isolates were categorized as multidrug-resistant (77%), extensively drug-resistant (11%), and pandrug-resistant (4%). A clear inverse correlation was observed between the presence of CRISPR/Cas systems and antibiotic resistance, with higher resistance rates in CRISPR/Cas-negative strains. These findings suggest that the absence of CRISPR/Cas may facilitate horizontal gene transfer, promoting the spread of resistance genes in K. pneumoniae.118 Moreover, another study aimed to investigate the underlying mechanisms of resistance, including extended-spectrum β-lactamases (ESBLs) and carbapenemases, and to determine whether a correlation exists between multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) Klebsiella pneumoniae isolates and the presence of CRISPR loci. A total of 100 isolates were analyzed for antimicrobial susceptibility using the VITEK AST card to identify ESBL and carbapenemase producers. Detection of CRISPR/Cas system genes was carried out through PCR. Among the isolates, 81 (81%) were resistant strains of K. pneumoniae, with 71 (71%) producing ESBLs and 21 (21%) producing carbapenemases. The resistance patterns revealed that 53% were MDR, 19% were XDR, and 9% were PDR. PCR results showed that Cas1, Cas3, CRISPR1, CRISPR2, and CRISPR3 genes were present in 38 (38%) isolates, while incomplete CRISPR1-Cas systems were detected in 78 (78%) isolates. The distribution of intact CRISPR types was as follows: CRISPR1 in 27%, CRISPR2 in 34%, and CRISPR3 in 18% of the isolates. Overall, the study demonstrated an inverse correlation between antibiotic resistance levels and the presence of CRISPR/Cas systems. The absence of CRISPR/Cas elements appeared to enhance the prevalence of MDR, XDR, and PDR phenotypes in ESBL- and carbapenemase-producing K. pneumoniae. As resistance severity increased from MDR to PDR, the frequency of CRISPR/Cas loci decreased correspondingly.1 Interestingly, it has been explored the presence of the CRISPR/Cas system in extensively and pan-drug-resistant Pseudomonas aeruginosa and used whole-genome sequencing (WGS) to analyze resistance mechanisms. Among 100 isolates, 54 were resistant, and 33% produced metallo-β-lactamase. CRISPR/Cas genes were detected in a minority (6–26%), while most XDR and PDR strains (87.8%) lacked CRISPR/Cas, showing higher antimicrobial resistance. WGS revealed unique resistance and virulence genes, suggesting that the absence of CRISPR/Cas may facilitate resistance gene acquisition. Overall, CRISPR/Cas and drug resistance appear antagonistic, underscoring WGS as a vital tool for understanding pseudomonal resistance.119 One key pathway involves the horizontal acquisition of conjugative plasmids carrying resistance genes by hvKp strains.30 Interestingly, hvKp has demonstrated a slower rate of acquiring resistance traits compared to cKp, possibly due to factors such as plasmid incompatibility, dense capsule production hindering DNA uptake, or the presence of CRISPR-Cas defense systems.120 Another mechanism is the integration of integrative and conjugative elements (ICEs) bearing resistance genes into the chromosome or virulence plasmid of hvKp.31,121,122 Klebsiella pneumoniae, a major antimicrobial-resistant pathogen, carries the integrative conjugative element ICEKp1, which spreads virulence genes and is common in invasive infections. A newly identified element, ICEKp2—similar to Pseudomonas aeruginosa’s PAPI—was found in carbapenem-resistant ST11, ST258, and ST512 strains. Although ICEKp2 could excise but not self-transfer, it enhanced plasmid mobilization by ICEKp1 via its Mob2 ATPase. This study reveals, for the first time, cooperation between two conjugative elements in K. pneumoniae, highlighting a novel mechanism of horizontal gene transfer.123 A study of OXA-48-producing Klebsiella pneumoniae isolates from the Netherlands (n=61) and Spain (n=53) revealed that most strains shared core virulence genes, including enterobactin, fim, mrk, and ureAD. The most common loci were KL17, KL24, and O1/O2v1. The yersiniabactin cluster—found in 67% of isolates—was distributed across multiple ICEKp elements, mainly in MDR lineages like ST11, ST101, and ST405. While no convergence between hypervirulence and resistance was observed, two isolates carried the colibactin cluster. The study underscores ICEKp’s central role in spreading key virulence factors such as yersiniabactin and colibactin among OXA-48-producing strains.124 Additionally, chromosomal mutations or disruptions—particularly in genes encoding OMPs—can contribute to resistance.121 Lastly, AMR may also emerge when MDR or XDR cKp strains acquire the hvKp virulence plasmid, resulting in the convergence of hypervirulence and high-level resistance.14 All K. pneumoniae strains, including hvKp variants, have intrinsic resistance to ampicillin and ticarcillin. Moreover, resistance to aminoglycosides, trimethoprim-sulfamethoxazole, tetracycline, and fluoroquinolones is often associated with conjugative or transferable plasmids that also carry genes encoding extended-spectrum β-lactamases (ESBLs) and carbapenemases.14 ESBLs, such as CTX-M, SHV, and TEM, are evolved forms of broad-spectrum β-lactamases that can break down third-generation cephalosporins, aztreonam, and in some cases, even fourth-generation cephalosporins, in addition to the usual β-lactam antibiotics.125,126 Gram-negative bacteria producing ESBLs may also have mutations in porin channels, leading to reduced permeability and limited uptake of cephalosporins, β-lactam/β-lactamase inhibitor combinations, and carbapenems—further diminishing their effectiveness. hvKp strains harboring ESBLs have been reported.127,128 AmpC β-lactamases, when highly expressed, provide resistance not only to the antibiotics targeted by ESBLs but also to cephamycins such as cefoxitin and cefotetan. Certain K. pneumoniae strains, including hvKp variants, have been found to acquire plasmids carrying genes that encode AmpC β-lactamases.128,129 Carbapenemases—including KPC (class A), NDM, VIM, and IMP (class B), as well as OXA-type enzymes (class D)—confer resistance not only to the agents targeted by ESBLs but also to cephamycins and carbapenems. The dissemination of these enzymes is often facilitated by transposons, such as Tn4401 for KPC.130–133 Recently, it has been characterized a clinical K. pneumoniae isolate (ST17, serotype KL38/O2) resistant to carbapenems. Its complete genome consists of a 5.1 Mb chromosome and two conjugative plasmids. The plasmid carries the blaIMP-4 carbapenemase gene and qnrS1, which confers quinolone resistance. The 272.7 kb FII(K)-9:FIB(K)-10 plasmid (pXH210-AMV) harbors multiple resistance genes against aminoglycosides, chloramphenicol, quinolones, tetracyclines, sulfonamides, trimethoprim, and various metals. Interestingly, the genome lacks typical hypervirulence-associated genes. Despite this, virulence assessment using a random forest predictive model and both Galleria mellonella and mouse infection models confirmed its hypervirulent phenotype, classifying it as a CR- hvKp strain. This alarming convergence of virulence and multidrug resistance, even in the absence of classical virulence markers, underscores the complexity of CR- hvKp pathogenesis.134 Notably, it has been revealed that a fatal hv-CRKp infection and its resistance evolution in a lung transplant patient over 1.5 years. Whole-genome sequencing revealed 11 ST11-KL64 KPC-producing CRKp strains and one carbapenem-susceptible ST412-KL57 strain. Colistin resistance arose via mgrB insertions and efflux pump activation, while ceftazidime/avibactam resistance was linked to blaKPC-2 mutations.135 A study investigated the molecular and epidemiological characteristics of polymyxin-resistant Klebsiella pneumoniae isolates from Brazilian hospitals. Isolates from two healthcare centers were analyzed phenotypically and via whole-genome sequencing (WGS) to determine sequence types, resistance genes, virulence factors, and plasmid profiles. Most isolates (80%) belonged to ST11, followed by ST345, ST15, and ST258. The resistome commonly included blaKPC-2, with additional genes such as blaSHV-11, blaTEM-1, blaCTX-M-15, and blaOXA-9, along with resistance determinants for aminoglycosides, fluoroquinolones, and tetracyclines. Clonal spread of polymyxin-resistant K. pneumoniae was linked mainly to mgrB gene disruptions by insertion sequences or nonsense mutations. A novel 78-bp repeat causing duplication of 26 amino acids in the MgrB protein was detected in six isolates—the first report of such a mechanism. These results indicate that mgrB alterations are the key drivers of polymyxin resistance in Brazil and emphasize the need for continuous genomic surveillance and strict infection control measures.136 Another study investigated colistin-resistant Klebsiella pneumoniae (CoR-Kp) isolates collected from 2021–2023 to explore mechanisms driving resistance. Among 127 isolates, 20 showed mgrB gene disruptions caused by insertion sequences (IS), mainly ISKpn26, ISKpn14, and IS903B, found in multiple sites. All mgrB-mutated strains belonged to ST11, exhibited multidrug resistance, and carried virulence genes such as rmpA2 and iroB. Results revealed both clonal and horizontal spread, with blaKPC and blaNDM frequently present. Overall, IS element–mediated mgrB mutations were identified as key drivers of colistin resistance in hypervirulent ST11 K. pneumoniae, emphasizing the urgent need for novel control strategies.137 Interesting, it has been reported the first isolation in Chile of a high-risk ST23 hvKp strain producing both KPC-2 and VIM-1 carbapenemases encoded on a single conjugative plasmid. The strain showed resistance to at least 15 antibiotic classes but lacked hypermucoviscosity despite carrying key hvKp virulence genes (K1 capsule, rmpA, iucABCDiutA). Whole-genome sequencing revealed its unique position within the CG23-I clonal group and the presence of a South American IncN plasmid with a class-I integron harboring blaVIM-1. The plasmid was transferable to E. coli, conferring broad β-lactam resistance. These findings underscore the ongoing evolution of hvKp toward multidrug resistance and highlight the role of mobile genetic elements in its global spread.138 A growing number of studies, particularly from Asia but not limited to it, have reported hvKp strains harboring carbapenemase genes. Among these, KPC acquisition appears most frequently, though strains producing NDM-1 and OXA variants have also been identified.14,130,133,139–141 Multiple mechanisms contributing to polymyxin resistance have been identified. Of particular concern is the emergence of the mcr-1 gene, which mediates resistance through a stable and transferable plasmid. This development is alarming, as polymyxins (including polymyxin B and colistin) are among the last-resort therapies against infections caused by metallo-β-lactamase-producing strains such as those harboring NDM-1. Worryingly, this resistance mechanism has also been reported in hvKp isolates.142 Another important mechanism underlying polymyxin resistance involves upregulation of the PhoP-PhoQ-Arn signaling pathway. When the PhoP-PhoQ system is activated, it induces overexpression of the arn operon, leading to the modification of lipid A by adding cationic groups to its phosphate residues. This modification reduces the overall negative charge on the bacterial surface, thereby diminishing the binding and efficacy of polymyxins. Additionally, mutations or insertions disrupting the mgrB gene—which encodes a negative regulator of the PhoP-PhoQ system—can further enhance this resistance mechanism.143 This resistance mechanism has also been documented in hvKp strains, highlighting the growing threat posed by these highly resistant and virulent pathogens.121 Tigecycline resistance has been observed in a cKp strain that transitioned into a hvKp following the acquisition of a segment of an hvKp-associated virulence plasmid. This resistance was linked to the overexpression of the efflux pump gene acrR and its regulator ramA, both known contributors to tigecycline resistance.14,144 It has been evaluated that antibiotic resistance in Klebsiella pneumoniae, MDR/XDR/PDR prevalence, and efflux pump and porin genes in 55 isolates from 120 clinical samples. High resistance was observed to ampicillin (100%), cefazolin/ceftriaxone (98.2%), and ceftazidime/cefepime (90.9%), with 57.2% MDR, 10.9% XDR, and 9.09% PDR. Efflux pump genes (acrAB 94.5%, tolC 89.1%) and porins (ompK35 96.4%, ompK36 98.2%) were prevalent, likely contributing to persistence and strong resistance in hospital settings.145 Diagnosis One of the major challenges in effectively managing patients with hvKp infections is the current inability of clinical microbiology laboratories to reliably differentiate hvKp from cKp Addressing this limitation requires the development and regulatory approval of a commercial diagnostic test capable of accurately identifying hvKp strains. Recognizing hvKp as the causative pathogen has important clinical implications. For instance, if hvKp infection had not been initially suspected, its identification would alert clinicians to the potential presence of occult metastatic infections. This would warrant further diagnostic imaging—such as CT or MRI—to detect any additional foci that may require intervention, including drainage or other forms of source control.3,13,14,146 Moreover, detecting hidden sites of infection—such as meningitis (which can be misinterpreted as sepsis-induced altered mental status), brain or prostatic abscesses, or endophthalmitis—is crucial. These conditions require targeted antimicrobial therapy that ensures sufficient drug penetration at the specific site to achieve the best possible clinical outcome.6 Endophthalmitis is a particularly severe and vision-threatening complication of hvKp infection. Ocular involvement may be absent or subtle at initial presentation, making early detection challenging. Because of the rapid progression and potential for irreversible ocular damage, prompt intervention is critical to preserve visual function. Therefore, in cases of confirmed or suspected hvKp infection, early consultation with an ophthalmologist is essential. This allows for thorough ocular assessment and, if necessary, the immediate initiation of appropriate therapy—such as intravitreal antibiotics and vitrectomy—to optimize visual outcomes.14,102 Conventional phenotypic methods—most notably the string test and the observation of hypermucoviscous colonies—are commonly employed for the preliminary screening of hvKp. Despite their widespread use, these methods possess significant limitations in accuracy and specificity. The string test is performed by gently stretching a bacterial colony on an agar plate using an inoculation loop; a positive result is indicated by the formation of a viscous filament exceeding 5 mm in length.147,148 This test is simple, rapid, and cost-effective, making it a practical tool for identifying the hypermucoviscous (HMV) phenotype, which is frequently—but not invariably—associated with hvKp. However, it is important to note that hypermucoviscosity and hypervirulence represent distinct biological traits. Some hvKp strains do not exhibit a hypermucoviscous phenotype, while conversely, certain hypermucoviscous isolates lack key virulence determinants and are not hypervirulent.12,147–151 Because of this partial overlap, reliance on the string test alone can lead to misclassification of isolates. To enhance diagnostic precision, the test should be supplemented with molecular detection of virulence-associated genes, such as rmpA, rmpA2, and iucA, which regulate capsule formation and siderophore production.12,147–151 Morphologically, hypermucoviscous colonies typically appear shiny, sticky, and elastic, but it is crucial to distinguish this from a merely mucoid appearance, which does not necessarily indicate true hypermucoviscosity. For optimal performance, the string test is usually conducted on MacConkey agar under aerobic conditions, which enhances phenotypic expression. Overall, while the string test remains a valuable initial screening tool, it should be interpreted cautiously and used in conjunction with confirmatory molecular assays to achieve accurate identification of hypervirulent K. pneumoniae strains.12,149 Fortunately, the presence of biomarkers such as peg-344, iroB, iucA, prmpA, prmpA2, along with siderophore production exceeding 30 μg/mL, has proven effective in reliably distinguishing hvKp strains from cKp.152 These biomarkers hold potential for the development of a diagnostic assay that, upon FDA approval, could be implemented in clinical microbiology laboratories to accurately identify hvKp strains. A test with high sensitivity and specificity is essential—not only to guide individual patient management but also to support surveillance efforts and advance research on hvKp.153 Total siderophore production, or the presence of iuc in combination with either rmpA or rmpA2, is likely to represent the most reliable and enduring marker of hypervirulence. It is reported that an XDR cKp strain acquired a hypervirulent phenotype even though the acquired hvKp plasmid lacked iro, peg-344, and rmpA, but retained iuc and rmpA2.14,33 The identification of genetic biomarkers can be readily accomplished using a PCR-based assay.154–157 Infections caused by hvKp frequently involve multiple anatomical sites either at initial presentation or through subsequent metastatic dissemination. While some sites of infection may be clinically evident through specific signs and symptoms, others may remain hidden and require imaging for detection.14,158 Looking ahead, CRISPR-based technologies also hold considerable promise for future diagnostic applications in microbiology. CRISPR-Cas technology, derived from the bacterial immune system, enables precise and efficient genome editing using Cas proteins and guide RNAs. It has revolutionized genetics, disease modeling, and therapeutic development, offering promise for treating genetic disorders, cancers, and infections. In microbiology, it serves as a powerful diagnostic and antibacterial tool. However, ethical, safety, and regulatory challenges—such as off-target effects and delivery issues—require careful evaluation before clinical application.159 Antibiotic Alternative Therapies Phage Therapy The rise of antibiotic resistance underscores the need for alternative treatments like bacteriophages. A study characterized phage M198, which targets K. pneumoniae strong lytic activity and no signs of lysogeny. Notably, phage M198 demonstrated synergistic effects when combined with trimethoprim, cefepime or chloramphenicol, highlighting its potential in combination therapy.160 Moreover, Severe infections caused by β-lactamase-producing hypervirulent Klebsiella pneumoniae (BhvKp), especially K2 serotypes, demand new treatment options. A study evaluated the therapeutic potential of a novel phage, PSKP16, in a mouse model of BhvKp-induced pneumonia. PSKP16, belonging to the Drexlerviridae family, showed strong biofilm inhibition and effectively reduced bacterial load and inflammation, especially with immediate treatment. Both phage alone and in combination with gentamicin improved survival, reduced lung damage, and normalized blood parameters. These findings highlight PSKP16 as a promising candidate for managing BhvKp-related pneumonia.161 On the other hand, Bacteriophages offer a potential treatment for hypervirulent, drug-resistant Klebsiella pneumoniae. It has been demonstrated that a phage cocktail (ΦK2044, ΦKR1, ΦKR8) targeting multiple capsular types effectively reduced biofilms, delayed resistance, and improved survival in insect and mouse models. These findings support its potential as a broad-spectrum phage therapy.162 Notably, another study presented two newly isolated phages, vB_Kpn_F13 and vB_Kpn_F14, from hospital sewage. Both demonstrated strong lytic activity, broad host range, and effective inhibition of resistant K. pneumoniae in planktonic and biofilm forms. Their stability under physiological conditions and similar efficacy suggest both are promising candidates for further preclinical and in vivo development.163 In addition, Phage therapy holds promise against hvKp), though resistance remains a challenge. It has been shown that phage ΦFK1979 was isolated from hospital sewage using a clinical K2-type hvKp strain (FK1979). While the bacteria rapidly developed phage resistance, this resistance led to reduced capsule production and virulence. Genetic analysis revealed mutations in capsule-related genes like rfaH and galU. Though resistance emerged quickly, the resulting hvKp mutants became less fit and more vulnerable to immune responses. New phages isolated from these mutants had larger genomes and broader host ranges.164 A study demonstrated the efficacy of K2-specific phages as antivirulence agents or in combinations to target both hvKp and its phage-resistant forms.164 The rise of carbapenem-resistant hvKp has prompted the search for alternative therapies. It has been identified three novel lytic phages—vB_KpnA_SCNJ1-Z, vB_KpnS_SCNJ1-C, and vB_KpnM_SCNJ1-Y—effective against the CR- hvKp strain SCNJ1. Despite a narrow host range, the phages showed strong biofilm inhibition, broad stability across pH and temperature ranges, and potent antibacterial activity. In a mouse infection model, both individual and combined phage treatments significantly reduced bacterial loads and improved survival rates (70–80%). These results highlight their potential as stable and effective alternatives for treating CR- hvKp infections165(Table 1). Table 1Summary of Recent Studies on Phage Therapy Against Klebsiella pneumoniaePhage/Phage CocktailKey FindingsReferenceM198Strong lytic activity, no lysogeny; synergistic with trimethoprim, cefepime, or chloramphenicol.[160]PSKP16 (Drexlerviridae)Reduced bacterial load, biofilm inhibition, and inflammation in mice; improved survival and reduced lung damage, especially with gentamicin.[161]ΦK2044, ΦKR1, ΦKR8 (Cocktail)Reduced biofilms, delayed resistance, improved survival in insect and mouse models; broad-spectrum phage therapy potential.[162]vB_Kpn_F13 and vB_Kpn_F14Strong lytic activity, broad host range, effective against planktonic and biofilm forms; stable under physiological conditions.[163]ΦFK1979 and newly isolated phagesRapid resistance development caused capsule loss and reduced virulence; new phages had larger genomes and broader host ranges, effective against hvKp variants.[164]vB_KpnA_SCNJ1-Z, vB_KpnS_SCNJ1-C, vB_KpnM_SCNJ1-YPotent lytic activity and biofilm inhibition; broad stability; significantly improved survival in mice (70–80%).[165] Table 1Summary of Recent Studies on Phage Therapy Against Klebsiella pneumoniaePhage/Phage CocktailKey FindingsReferenceM198Strong lytic activity, no lysogeny; synergistic with trimethoprim, cefepime, or chloramphenicol.[160]PSKP16 (Drexlerviridae)Reduced bacterial load, biofilm inhibition, and inflammation in mice; improved survival and reduced lung damage, especially with gentamicin.[161]ΦK2044, ΦKR1, ΦKR8 (Cocktail)Reduced biofilms, delayed resistance, improved survival in insect and mouse models; broad-spectrum phage therapy potential.[162]vB_Kpn_F13 and vB_Kpn_F14Strong lytic activity, broad host range, effective against planktonic and biofilm forms; stable under physiological conditions.[163]ΦFK1979 and newly isolated phagesRapid resistance development caused capsule loss and reduced virulence; new phages had larger genomes and broader host ranges, effective against hvKp variants.[164]vB_KpnA_SCNJ1-Z, vB_KpnS_SCNJ1-C, vB_KpnM_SCNJ1-YPotent lytic activity and biofilm inhibition; broad stability; significantly improved survival in mice (70–80%).[165] Summary of Recent Studies on Phage Therapy Against Klebsiella pneumoniae Antimicrobial Peptide Polymyxin-resistant K. pneumoniae poses a serious threat by limiting treatment options. Antimicrobial peptides (AMPs), part of the innate immune response, are emerging as promising alternatives. A study analyzed patents on AMPs targeting polymyxin-resistant K. pneumoniae, identifying only 14 relevant patents among 1313, all in early experimental or pre-clinical stages. While promising, further investment is essential to advance AMP development into clinical use and address this growing resistance problem.166 In another study evaluated Osmin, a 17-amino acid peptide from Osmia rufa bee venom, as a potential alternative therapy. Osmin showed strong antimicrobial and anti-biofilm effects, low toxicity, high stability, and a low risk of resistance. In mice with CRKP-induced sepsis, it significantly reduced bacterial load and inflammation. These findings support Osmin’s potential as a promising treatment for drug-resistant K. pneumoniae infections.167 Notably, AMPs often face clinical limitations due to toxicity, short half-life, and low effectiveness against gram-negative bacteria. A study evaluated two nanoparticle-based formulations of the AMP AA139—polymeric nanoparticles (AA139-PNP) and lipid-core micelles (AA139-MCL)—to improve its therapeutic potential. Both formulations showed strong in vitro activity, extended lung retention, reduced toxicity, and enhanced survival in a rat model of K. pneumoniae-induced pneumonia-septicemia. These findings suggest AA139-nanomedicines could be promising treatments for multidrug-resistant gram-negative infections.168 Another study evaluated four AMPs against gentamicin-resistant strains. These strains showed increased resistance and upregulation of efflux pump, porin, and biofilm genes. The AMPs significantly reduced biofilm formation, efflux pump activity, and bacterial damage in both cell and mouse pneumonia models. Among the tested peptides, KLA demonstrated the strongest antibacterial effect. These findings support AMPs—particularly KLA—as promising candidates for treating resistant K. pneumoniae infections.169 Another study identified and purified a novel AMP named Cm38 from Centruroides margaritatus scorpion venom. Cm38 showed antimicrobial activity against Klebsiella pneumoniae with an MIC of 64 μM. Structurally related to the sodium channel toxin Cn11, Cm38 also affected neuronal activity by depolarizing and increasing action potential firing in dorsal root ganglion neurons. These findings highlight Cm38 as a dual-function peptide with both antimicrobial and neuroactive properties.170 (Table 2). Table 2Summary of Antimicrobial Peptides (AMPs) Targeting Klebsiella pneumoniaeAMP/StrategySource/TypeKey FindingsReferenceOsminBee venom peptide (Osmia rufa)Strong antimicrobial and anti-biofilm activity; low toxicity; reduced bacterial load and inflammation in sepsis mouse model.[167]AA139-PNP and AA139-MCLNanoparticle formulations of AMP AA139Improved in vitro activity and lung retention; reduced toxicity; enhanced survival in rat pneumonia-septicemia model.[168]KLA and 3 other AMPsSynthetic peptidesReduced biofilm and efflux pump activity; downregulated resistance genes; KLA showed strongest antibacterial effect in mouse and cell models.[169,170]Cm38Scorpion venom (Centruroides margaritatus)MIC = 64 μM; antimicrobial and neuroactive (affects neuronal depolarization); dual-function activity with sodium channel interaction.[170] Table 2Summary of Antimicrobial Peptides (AMPs) Targeting Klebsiella pneumoniaeAMP/StrategySource/TypeKey FindingsReferenceOsminBee venom peptide (Osmia rufa)Strong antimicrobial and anti-biofilm activity; low toxicity; reduced bacterial load and inflammation in sepsis mouse model.[167]AA139-PNP and AA139-MCLNanoparticle formulations of AMP AA139Improved in vitro activity and lung retention; reduced toxicity; enhanced survival in rat pneumonia-septicemia model.[168]KLA and 3 other AMPsSynthetic peptidesReduced biofilm and efflux pump activity; downregulated resistance genes; KLA showed strongest antibacterial effect in mouse and cell models.[169,170]Cm38Scorpion venom (Centruroides margaritatus)MIC = 64 μM; antimicrobial and neuroactive (affects neuronal depolarization); dual-function activity with sodium channel interaction.[170] Summary of Antimicrobial Peptides (AMPs) Targeting Klebsiella pneumoniae Antibiotic Combination Therapy Combination therapy is crucial for treating metallo-β-lactamase-producing K. pneumoniae (MBL-KP), but optimal combinations remain unclear. This study tested double and triple antibiotic combinations in time-kill assays against VIM- and NDM-producing strains. The most effective regimen was rifampin-meropenem-colistin, which showed both synergistic and bactericidal activity. Other effective pairs included colistin with aztreonam, fosfomycin, or rifampin. However, some commonly used combinations like meropenem-colistin and tigecycline-colistin lacked bactericidal activity. These results highlight the need for more targeted research on MBL-KP, as current data largely focus on KPC-producing strains.171 CR-hvKp poses a serious treatment challenge. It has been shown that 65 CR-hvKp isolates were tested in vitro, and ceftazidime-avibactam, colistin, and tigecycline showed strong activity (MIC90 ≤1 μg/mL), including against KPC-2-producing ST11 strains. Based on these findings and existing clinical data, ceftazidime-avibactam appears to be a promising therapeutic option for CR-hvKp infections.172 Notably, a study assessed the effect of high-dose carbapenem-based combination therapy on outcomes in 595 patients with bloodstream infections caused by carbapenem-resistant K. pneumoniae. Multivariate analysis revealed that high dose carbapenem therapy was associated with reduced 14-day mortality, even in cases with high-level resistance (MIC ≥16 mg/L). Protective factors included surgical ward admission and high dose carbapenem use, while septic shock, high comorbidity, and colistin resistance were linked to higher mortality. These findings suggest that high dose carbapenem combinations may improve outcomes in CR-KP bloodstream infections.173 Moreover, another study investigated the in vitro effectiveness of various antibiotic combinations against multidrug-resistant Klebsiella pneumoniae (MDR-KP) from ventilator-associated pneumonia (VAP) cases. All 10 carbapenem-resistant isolates were resistant to multiple drugs. In planktonic form, combinations like colistin-meropenem and amoxicillin/clavulanate-based therapies showed synergy in 60–70% of cases. In biofilm form, colistin-amikacin was the most effective, with 70% synergy. These findings suggest that specific colistin-based combinations may offer promising treatment options for MDR-KP infections in both planktonic and biofilm states.174 In addition, it has been evaluated the in vitro efficacy of various antimicrobial combinations—both colistin-based and colistin-free—against 39 carbapenem-resistant Klebsiella pneumoniae (CR-Kp) isolates. Colistin combinations (especially colistin + rifampicin) showed high synergy, including in colistin-resistant strains. The double-carbapenem regimen (meropenem + ertapenem) showed moderate synergy, particularly in strains with lower meropenem MICs (≤128 mg/L). Findings highlight the importance of synergy testing and MIC-based evaluations to guide effective treatment strategies for CR-Kp infections.175 Moreover, colistin with rifampin or in triple combinations (colistin + meropenem + tigecycline) inhibited most of the isolates176 (Table 3). Table 3Summary of Combination Therapy Strategies for Drug-Resistant Klebsiella pneumoniaeCombination/ApproachKey FindingsReferenceRifampin + Meropenem + ColistinSynergistic and bactericidal in time-kill assays; most effective among tested combinations.[171]Colistin + Aztreonam/Fosfomycin/RifampinShowed strong synergy; more effective than meropenem-colistin or tigecycline-colistin, which lacked bactericidal activity.[171]Ceftazidime-AvibactamMIC90 ≤1 μg/mL; potent in vitro activity; promising clinical treatment option for CR-hvKP infections.[172]High-Dose Carbapenem-Based TherapyReduced 14-day mortality, even at MIC ≥16 mg/L; protective effect with surgical admission and high-dose carbapenem; septic shock increased mortality.[173]Colistin + Meropenem/Amoxicillin-ClavulanateIn planktonic form, synergy in 60–70% of isolates; colistin-amikacin most effective in biofilm form with 70% synergy.[174]Meropenem + Ertapenem (Double-carbapenem)Moderate synergy, especially in strains with lower meropenem MICs (≤128 mg/L); importance of MIC-guided therapy.[175]Colistin + Rifampin/Meropenem/TigecyclineColistin + rifampin highly synergistic; triple combo (colistin + meropenem + tigecycline) inhibited 94.8% of isolates.[176] Table 3Summary of Combination Therapy Strategies for Drug-Resistant Klebsiella pneumoniaeCombination/ApproachKey FindingsReferenceRifampin + Meropenem + ColistinSynergistic and bactericidal in time-kill assays; most effective among tested combinations.[171]Colistin + Aztreonam/Fosfomycin/RifampinShowed strong synergy; more effective than meropenem-colistin or tigecycline-colistin, which lacked bactericidal activity.[171]Ceftazidime-AvibactamMIC90 ≤1 μg/mL; potent in vitro activity; promising clinical treatment option for CR-hvKP infections.[172]High-Dose Carbapenem-Based TherapyReduced 14-day mortality, even at MIC ≥16 mg/L; protective effect with surgical admission and high-dose carbapenem; septic shock increased mortality.[173]Colistin + Meropenem/Amoxicillin-ClavulanateIn planktonic form, synergy in 60–70% of isolates; colistin-amikacin most effective in biofilm form with 70% synergy.[174]Meropenem + Ertapenem (Double-carbapenem)Moderate synergy, especially in strains with lower meropenem MICs (≤128 mg/L); importance of MIC-guided therapy.[175]Colistin + Rifampin/Meropenem/TigecyclineColistin + rifampin highly synergistic; triple combo (colistin + meropenem + tigecycline) inhibited 94.8% of isolates.[176] Summary of Combination Therapy Strategies for Drug-Resistant Klebsiella pneumoniae Recent studies have revealed various antibiotic combination strategies to fight hv-CRKp, showing encouraging in vitro and clinical outcomes. Among them, the combination of rifampin, meropenem, and colistin demonstrated strong synergistic and bactericidal effects, outperforming other regimens.135 Likely, colistin combined with aztreonam, fosfomycin, or rifampin exhibited significant synergy, while meropenem- or tigecycline-based combinations were less effective.171 Ceftazidime-avibactam showed potent activity (MIC90 ≤ 1 µg/mL), making it a promising option for CR-hvKp treatment.172 High dose carbapenem regimens were linked to lower mortality rates, emphasizing the role of dose optimization.173 In biofilm and planktonic forms, colistin-amikacin and colistin-meropenem combinations yielded substantial synergy.174 Double-carbapenem therapy (meropenem + ertapenem) also showed moderate synergy, especially against strains with lower MICs, supporting MIC-guided therapeutic approaches.175 Moreover, colistin with rifampin or in triple combinations (colistin + meropenem + tigecycline) inhibited most of the isolates.176 These findings suggest that combination therapy may offer a viable strategy to enhance treatment efficacy against hv-CRKp, particularly when guided by MIC values and infection type (planktonic vs. biofilm). However, standardized clinical trials are urgently needed to validate these in vitro observations. Future research should focus on optimizing dosing regimens, evaluating pharmacodynamic interactions in vivo, and developing novel synergistic combinations that minimize toxicity while overcoming resistance mechanisms. Discussion Hypervirulent Klebsiella pneumoniae (hvKp) has emerged as a major global threat, exhibiting greater virulence than classical K. pneumoniae (cKp) and causing severe community-acquired infections, often in healthy individuals. Colonization of the gastrointestinal tract facilitates both community and hospital transmission. Initially identified in Asia as a leading cause of pyogenic liver abscess, hvKp has since spread worldwide, causing diverse infections such as bacteremia, pneumonia, and soft tissue infections, with frequent metastatic spread to the eye, lungs, and central nervous system.50 Clinical and molecular evidence indicates that K. pneumoniae infections often originate from the gastrointestinal tract, although the mechanisms underlying intestinal barrier penetration remain poorly understood. It has been elucidated that both bacteremic and PLA clinical isolates were capable of adhering to and invading intestinal epithelial cells. Confocal microscopy and three-dimensional (3D) imaging confirmed the internalization of K. pneumoniae within three different human colonic cell lines. Using a Transwell system, it demonstrated that these isolates were able to translocate across polarized Caco-2 monolayers without affecting transepithelial electrical resistance or the localization of tight junction proteins ZO-1 and occludin, suggesting a transcellular route of passage. Further mechanistic investigations using specific inhibitors showed that actin and microtubule cytoskeletal components play essential roles in bacterial invasion, as indicated by inhibition with cytochalasin D and nocodazole. Additionally, inhibitors targeting Rho GTPases (ML141), PI3K (LY294002), and Akt1/2 reduced bacterial invasion in a dose-dependent manner, confirming the involvement of Rho family GTPases and the PI3K/Akt signaling pathway. Additionally in a mouse model of gastrointestinal colonization, in vivo invasion of K. pneumoniae into colonic epithelial cells was observed. Collectively, these results provide strong evidence that K. pneumoniae can translocate across the intestinal barrier through active invasion of epithelial cells, utilizing host cytoskeletal and signaling machinery. This mechanism may explain how gut-colonizing K. pneumoniae gains access to extraintestinal sites, leading to systemic infection and disease. Conclusion The clinical threat posed by hypervirulent Klebsiella pneumoniae (hvKp) continues to grow due to its increasing antimicrobial resistance and ability to cause severe, invasive infections. This dual threat underscores the urgent need for enhanced diagnostic tools, robust surveillance systems, and innovative therapeutic strategies. Current advances in phage therapy, antimicrobial peptides (AMPs), and nanomedicine-based formulations offer promising avenues for future treatment; however, their translation into clinical practice will require addressing key challenges related to efficacy, targeted delivery, safety, and regulatory approval. Future research should focus on developing rapid, cost-effective diagnostic assays capable of distinguishing hvKp from classical strains in routine clinical settings. Moreover, integrating genomic surveillance with clinical data could help predict emerging resistance and virulence trends. A coordinated, multidisciplinary approach involving microbiologists, clinicians, and pharmacologists will be essential to translate laboratory discoveries into practical medical interventions. Ultimately, improved awareness, early detection, and tailored therapeutic strategies will be critical to mitigating hvKp-related morbidity and mortality in the coming years.